Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Noninsulin-Dependent
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- NIDDM
- Diabetes Mellitus, Noninsulin Dependent
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Noninsulin-Dependent Diabetes Mellitus
- Noninsulin Dependent Diabetes Mellitus
- Maturity-Onset Diabetes
- Diabetes, Maturity-Onset
- Maturity Onset Diabetes
- Type 2 Diabetes
- Diabetes, Type 2
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 |
| 1997 | 2 | 0 | 2 |
| 1998 | 4 | 0 | 4 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 1 | 4 |
| 2002 | 4 | 1 | 5 |
| 2003 | 4 | 2 | 6 |
| 2004 | 14 | 1 | 15 |
| 2005 | 11 | 5 | 16 |
| 2006 | 7 | 1 | 8 |
| 2007 | 14 | 3 | 17 |
| 2008 | 19 | 1 | 20 |
| 2009 | 6 | 0 | 6 |
| 2010 | 7 | 1 | 8 |
| 2011 | 8 | 1 | 9 |
| 2012 | 12 | 1 | 13 |
| 2013 | 13 | 1 | 14 |
| 2014 | 17 | 2 | 19 |
| 2015 | 15 | 5 | 20 |
| 2016 | 15 | 1 | 16 |
| 2017 | 20 | 2 | 22 |
| 2018 | 19 | 4 | 23 |
| 2019 | 20 | 1 | 21 |
| 2020 | 15 | 1 | 16 |
| 2021 | 21 | 1 | 22 |
| 2022 | 20 | 0 | 20 |
| 2023 | 9 | 0 | 9 |
| 2024 | 13 | 2 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Amaral DC, Guedes J, Cruz MRB, Cheidde L, Nepomuceno M, Magalh?es PLM, Brazuna R, Mora-Paez DJ, Huang P, Razeghinejad R, Schuman JS, Myers JS. GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025 Mar; 271:488-497.
-
Rovner BW, Casten RJ. Discordant Medication Beliefs in Black Individuals With Mild Cognitive Impairment and Diabetes. Am J Geriatr Psychiatry. 2025 04; 33(4):337-341.
-
Simonson DC, Testa MA, Ekholm E, Su M, Vilsb?ll T, Jabbour SA, Lind M. Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine. J Clin Endocrinol Metab. 2024 11 18; 109(12):e2261-e2272.
-
Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024 07 15; 23(1):252.
-
Brownlee HA, Soriano EC, Lenhard MJ, Fenech AL, Morreale M, Siegel SD, Bolger N, Laurenceau JP. Romantic relationships and type 2 diabetes: The role of invisible social control. Health Psychol. 2024 Oct; 43(10):739-746.
-
Weintraub WS, Kolm P, Dolman S, Alva M, Bhatt DL, Zhang Z. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF. JACC Heart Fail. 2024 09; 12(9):1600-1610.
-
Idowu A, Adebolu O, Bruce C, Nriagu B, Evbayekha E, Lo KB, Afolabi-Brown O, Rangaswami J. Invasive Hemodynamic Changes Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cardiovasc Ther. 2024; 2024:2735577.
-
Pate A, Sperrin M, Riley RD, Peek N, Van Staa T, Sergeant JC, Mamas MA, Lip GYH, O'Flaherty M, Barrowman M, Buchan I, Martin GP. Calibration plots for multistate risk predictions models. Stat Med. 2024 06 30; 43(14):2830-2852.
-
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.
-
Larson S, Beaupr? J, Kjelstrom S, Schwartz S, Hartz W, Massuda J. A Comparison of Emergency Room Visits and Hospital Admissions Between People with Prediabetes and Diabetes. Popul Health Manag. 2024 08; 27(4):241-248.